EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.269
https://www.valueinhealthjournal.com/article/S1098-3015(22)02473-1/fulltext
Title :
EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02473-1&doi=10.1016/j.jval.2022.09.269
First page :
Section Title :
Open access? :
No
Section Order :
12071